{"nctId":"NCT00395733","briefTitle":"Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients","startDateStruct":{"date":"2006-10"},"conditions":["Vascular Diseases"],"count":83,"armGroups":[{"label":"Gadobutrol, then Gadopentate dimeglumine","type":"EXPERIMENTAL","interventionNames":["Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Drug: Gadopentate dimeglumine (Magnevist, BAY86-4882)"]},{"label":"Gadopentate, dimeglumine then Gadobutrol","type":"EXPERIMENTAL","interventionNames":["Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Drug: Gadopentate dimeglumine (Magnevist, BAY86-4882)"]}],"interventions":[{"name":"Gadobutrol (Gadavist, Gadovist, BAY86-4875)","otherNames":[]},{"name":"Gadopentate dimeglumine (Magnevist, BAY86-4882)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chinese origin\n* Known or suspected blood vessel diseases\n\nExclusion Criteria:\n\n* Pregnancy\n* Lactation\n* Conditions interfering with MRI\n* Allergy to any contrast agent or any drugs\n* Participation in other trial\n* Require emergency treatment\n* Severely impaired liver and kidney functions","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Vessel Segments Visualized With Diagnostic Quality","description":"Each arterial segment visualized in magnetic resonance angiography (MRA) enhanced by Gadavist and Magnevist was characterized by the on-site investigators and by three independent blinded readers (reader 1, 2 and 3) according to a five-point scale (none/not assessable, poor, moderate, good, excellent), which takes into consideration intravascular contrast quality as well as vessel border delineation. The number of vessel segments with adequate diagnostic quality, i.e. good or excellent scores, was determined for each MRA image.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.10","spread":"3.685"},{"groupId":"OG001","value":"8.33","spread":"3.755"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.03","spread":"3.815"},{"groupId":"OG001","value":"8.33","spread":"3.852"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.55","spread":"4.622"},{"groupId":"OG001","value":"7.88","spread":"3.665"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.27","spread":"3.921"},{"groupId":"OG001","value":"5.91","spread":"3.666"}]}]}]},{"type":"SECONDARY","title":"Change in Diagnostic Confidence From Pre- to Post-contrast MRA by Investigator","description":"The on-site investigators assessed the change in diagnostic confidence in the assessment of MRA scans before and after injection with Gadavist and Magnevist for each participant on a three-point scale as improved, unchanged or worsened.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Diagnostic Confidence From Pre- to Post-contrast MRA by Blinded Reader 1","description":"Independent blinded reader 1 assessed the change in diagnostic confidence in the assessment of MRA scans before and after injection with Gadavist and Magnevist for each participant on a three-point scale as improved, unchanged or worsened.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Diagnostic Confidence From Pre- to Post-contrast MRA by Blinded Reader 2","description":"Independent blinded reader 2 assessed the change in diagnostic confidence in the assessment of MRA scans before and after injection with Gadavist and Magnevist for each participant on a three-point scale as improved, unchanged or worsened.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Diagnostic Confidence From Pre- to Post-contrast MRA by Blinded Reader 3","description":"Independent blinded reader 3 assessed the change in diagnostic confidence in the assessment of MRA scans before and after injection with Gadavist and Magnevist for each participant on a three-point scale as improved, unchanged or worsened.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"MRA Diagnosis by Investigators","description":"The MRA diagnosis describes the pathology with regard to the extent of a stenosis, i.e., normal (no relevant disease), advanced arteriosclerosis but stenosis \\<= 50% (exemption: internal carotid artery: stenosis \\<= 70%), advanced arteriosclerosis, stenosis \\>50% but \\<99% (stenosis 50-99%) (exemption: internal carotid artery \\>70%), occlusion, and not assessable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"494","spread":null},{"groupId":"OG001","value":"504","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"271","spread":null},{"groupId":"OG001","value":"278","spread":null}]}]}]},{"type":"SECONDARY","title":"MRA Diagnosis by Blinded Reader 1","description":"The MRA diagnosis describes the pathology with regard to the extent of a stenosis, i.e., normal (no relevant disease), advanced arteriosclerosis but stenosis \\<= 50% (exemption: internal carotid artery: stenosis \\<= 70%), advanced arteriosclerosis, stenosis \\>50% but \\<99% (stenosis 50-99%) (exemption: internal carotid artery \\>70%), occlusion, and not assessable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"503","spread":null},{"groupId":"OG001","value":"497","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"272","spread":null},{"groupId":"OG001","value":"273","spread":null}]}]}]},{"type":"SECONDARY","title":"MRA Diagnosis by Blinded Reader 2","description":"The MRA diagnosis describes the pathology with regard to the extent of a stenosis, i.e., normal (no relevant disease), advanced arteriosclerosis but stenosis \\<= 50% (exemption: internal carotid artery: stenosis \\<= 70%), advanced arteriosclerosis, stenosis \\>50% but \\<99% (stenosis 50-99%) (exemption: internal carotid artery \\>70%), occlusion, and not assessable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"503","spread":null},{"groupId":"OG001","value":"549","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":null},{"groupId":"OG001","value":"224","spread":null}]}]}]},{"type":"SECONDARY","title":"MRA Diagnosis by Blinded Reader 3","description":"The MRA diagnosis describes the pathology with regard to the extent of a stenosis, i.e., normal (no relevant disease), advanced arteriosclerosis but stenosis \\<= 50% (exemption: internal carotid artery: stenosis \\<= 70%), advanced arteriosclerosis, stenosis \\>50% but \\<99% (stenosis 50-99%) (exemption: internal carotid artery \\>70%), occlusion, and not assessable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"489","spread":null},{"groupId":"OG001","value":"499","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"321","spread":null},{"groupId":"OG001","value":"308","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":78},"commonTop":["Palpitations","C-reactive protein increased","Nausea","Vertigo","Rash papular"]}}}